1-anilino-8-naphthalenesulfonate has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, A; Arén Frontera, O; Barthélémy, P; Beuselinck, B; Bracarda, S; Carducci, MA; Choueiri, TK; Donskov, F; Duran, I; Escudier, B; George, S; Grimm, MO; Grünwald, V; Gurney, H; Hammers, HJ; Harrison, MR; Heng, DYC; Kollmannsberger, CK; Leibowitz-Amit, R; McDermott, DF; McHenry, MB; Mekan, S; Melichar, B; Motzer, RJ; Nathan, P; Neiman, V; Oosting, SF; Oudard, S; Plimack, ER; Pook, D; Porta, C; Powles, T; Redman, B; Rini, BI; Salman, P; Tannir, NM; Tomita, Y; Tykodi, SS | 1 |
| Barthélémy, P; Bennamoun, M; Bensalah, K; Bernhard, JC; Beuzeboc, P; Borchiellini, D; Bougouïn, A; Braychenko, E; Cancel, M; Caruso, S; Cathelineau, X; Chevreau, C; Coquan, E; de la Taille, A; Doumerc, N; Elaidi, R; Fournier, L; Fridman, WH; Gravis, G; Gross-Goupil, M; Houede, N; Huillard, O; Lacroix, G; Laguerre, B; Maillet, D; Méjean, A; Meylan, M; Moreira, M; Oudard, S; Pannier, D; Paparel, P; Phan, L; Pignot, G; Sautès-Fridman, C; Sun, CM; Thibault-Carpentier, C; Tournigand, C; Tricard, T; Vano, YA; Verkarre, V; Waeckel, T; Zucman-Rossi, J | 1 |
2 trial(s) available for 1-anilino-8-naphthalenesulfonate and su 11248
| Article | Year |
|---|---|
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Topics: Alanine Transaminase; Amylases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypertension; Intention to Treat Analysis; Ipilimumab; Kidney Neoplasms; Lipase; Nivolumab; Paresthesia; Progression-Free Survival; Sunitinib; Survival Rate | 2019 |
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Ipilimumab; Lipase; Male; Neoplasm Staging; Nivolumab; Prospective Studies; Protein Kinase Inhibitors; Sunitinib; Tumor Microenvironment | 2022 |